These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2429367)
1. Interferons in the treatment of multiple myeloma. Cooper MR; Welander CE Semin Oncol; 1986 Sep; 13(3):334-40. PubMed ID: 2429367 [No Abstract] [Full Text] [Related]
2. [Interferon in the treatment of multiple myeloma]. Kuzmits R; Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Flener R; Scheithauer W Acta Med Austriaca; 1985; 12(5):135-8. PubMed ID: 3914174 [TBL] [Abstract][Full Text] [Related]
3. Interferons in the treatment of multiple myeloma. Cooper MR; Welander CE Cancer; 1987 Feb; 59(3 Suppl):594-600. PubMed ID: 3802025 [TBL] [Abstract][Full Text] [Related]
4. Interferons in the treatment of multiple myeloma. Cooper MR Semin Oncol; 1986 Sep; 13(3 Suppl 2):13-20. PubMed ID: 3764441 [TBL] [Abstract][Full Text] [Related]
5. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies and controversies in the treatment of multiple myeloma. Bladé J Pathol Biol (Paris); 1999 Feb; 47(2):192-8. PubMed ID: 10192888 [TBL] [Abstract][Full Text] [Related]
7. Interferons in the management of multiple myeloma. Cooper MR Semin Oncol; 1988 Oct; 15(5 Suppl 5):21-5. PubMed ID: 3057642 [No Abstract] [Full Text] [Related]
8. Treatment of refractory multiple myeloma and considerations for future therapy. Kyle RA; Greipp PR; Gertz MA Semin Oncol; 1986 Sep; 13(3):326-33. PubMed ID: 3532331 [No Abstract] [Full Text] [Related]
9. [Monoclonal gammapathy of indeterminate origin and myeloma]. Bury J; Salmon J; Fillet G Rev Med Liege; 1988 Apr; 43(8):270-4. PubMed ID: 3285431 [No Abstract] [Full Text] [Related]
10. Diagnosis and management of multiple myeloma. UK myeloma forum. British Committee for Standards in Haematology Br J Haematol; 2001 Dec; 115(3):522-40. PubMed ID: 11736932 [No Abstract] [Full Text] [Related]
11. Results and further perspectives of plasmocytoma chemotherapy. Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353 [TBL] [Abstract][Full Text] [Related]
12. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group. Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374 [No Abstract] [Full Text] [Related]
13. The therapy of multiple myeloma with the interferons. Bonnem EM Cancer Treat Rev; 1988 Jan; 15 Suppl A():35-41. PubMed ID: 2449280 [No Abstract] [Full Text] [Related]
14. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002 [TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma. Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108 [No Abstract] [Full Text] [Related]
16. [Interferon: a new weapon in the therapeutic strategy of multiple myeloma]. Avvisati G; Petrucci MT; Mandelli F Haematologica; 1990; 75 Suppl 4():68-71. PubMed ID: 1705913 [No Abstract] [Full Text] [Related]